Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
RegulatoryapprovedZENBEXUSPositive
AI Analysis
Summary
Bristol Myers Squibb's ZENBEXUS (iberdomide) received FDA accelerated approval as the first CELMoD therapy for multiple myeloma, with Hematogenix's MM MRD assay measuring the primary efficacy endpoint in the registration trial.
Outcome Details
FDA accelerated approval for ZENBEXUS (iberdomide), first approved CELMoD therapy for multiple myeloma
Importance:8/10
Sentiment:
0.85
FDA approvalAccelerated approvalMultiple myelomaDiagnostic assayCELMoD
Related Companies
Read the original article
Published by PR Newswire Biotech on August 19, 2026 12:32 PM